Current Study Opportunities at The CRC

Studies at CRC can change frequently. For the most up to date information of current enrolling studies please fill out the form on the right or call 314-514-8509 ext 12 to see if you qualify for a study. Studies listed were updated on 03/2026.

Study #1: Investigational GLP-1 research trial to learn more about the safety and tolerability of an investigational oral GLP-1 medication and how it affects your blood glucose levels and body weight. The main purpose of this study is to find out if the study drug, either alone or in combination with another drug can help people with T2DM improve their overall health.

Brief description of study

This investigational research study is enrolling participants with type 2 diabetes (T2DM) whose condition is inadequately managed with lifestyle management alone or treated daily with metformin. Participants must have been diagnosed with type 2 diabetes for at least 90 days and have a BMI above or equal to 23 kg/m 2 and maintaining stable body weight for at least the last 90 days (no significant changes of more than ±5%). The study requires approximately 12 on-site visits over approximately 46 weeks (about 10.5 months).

Compensation for participation may be provided for those who qualify. Please fill out the Volunteer Questionnaire or call 314-514-8509

Study #2: Investigational mRNA seasonal flu vaccine research study for adults aged 65 and older.

Brief description of study

This phase 3 vaccine research study is comparing an investigational mRNA-based seasonal influenza vaccine to a licensed high-dose seasonal flu vaccine. To participate, you must be at least 65 years old and medically stable. The study requires at least 2 on-site visits and 2 phone calls over 6-8 months.

Compensation for participation may be provided for those who qualify. Please fill out the Volunteer Questionnaire or call 314-514-8509

Study #3: Clinical Research Study to learn about an investigational add-on therapy for those with COPD who have flared within the past 12 months despite daily inhaled maintenance treatment

Brief description of study

This investigational research study is enrolling participants with COPD who are on triple inhaled therapy (ICS/LABA/LAMA; ex. Breztri, Trelegy) or double inhaled therapy, such as ICS/LABA (ex. Symbicort, Advair, etc.), LAMA/LABA (ex. Stiolto, Anoro) or ICS + LAMA (ex. Spiriva) who flared while taking their stable maintenance medication. A severe flare may include admission to the hospital, and a moderate flare can include treatment with antibiotics and/or systemic corticosteroids. Participants must be current or former smokers with a smoking history ≥ 10 pack years. The study requires 9 on-site visits over approximately 7 months (30 weeks).

Compensation for participation may be provided for those who qualify. Please fill out the Volunteer Questionnaire or call 314-514-8509

Study #4: Phase 2 clinical research trial to study if an investigational oral medication is safe for adults with moderate-to-severe asthma and if it can prevent asthma symptoms from becoming uncontrolled in participants who stop taking LABA and ICS medications

Brief description of study

This investigational research study is enrolling participants who have had asthma for at least 12 months and who are currently taking a stable regimen of medium-to-high dose ICS in combination with LABA (for example, Symbicort, Advair, Dulera, etc.) for at least the past 2 months. Participants must be non-smokers without a significant smoking history. Participants must have experienced one of the following exacerbation events within the past year: treatment with systemic steroids for worsening asthma or hospitalization or emergency medical care visit for worsening asthma. The study requires 7 on-site visits over approximately 4-5 months.

Compensation for participation may be provided for those who qualify. Please fill out the Volunteer Questionnaire or call 314-514-8509

Study #5: This study is being performed to learn more about an investigational drug for adults with Type 2 Diabetes (T2DM) who are living with Obesity or Overweight and T2DM.

Brief description of study

This investigational research study is enrolling participants who have T2DM and a BMI (Body Mass Index) of at least 27 kg/m 2 who have previously tried unsuccessfully to lose weight and have maintained stable body weight (no significant changes of more than ±5%) for at least the last 90 days. The investigational drug is a once weekly injection under the skin. The study requires about 16 visits over approximately one and half years.

Compensation for participation may be provided for those who qualify. Please fill out the Volunteer Questionnaire or call 314-514-8509